Why AI matters at this scale

Mylan, now part of Viatris but operating as a distinct global brand, is a cornerstone of the generic pharmaceuticals industry. With over 10,000 employees, a vast portfolio of medicines, and manufacturing and commercial operations spanning the globe, the company operates at a scale where marginal efficiency improvements yield massive financial and societal impact. In the low-margin, high-volume generics sector, competitive advantage is won through operational excellence, supply chain resilience, and accelerated development of complex products. Artificial Intelligence presents a transformative lever across this entire value chain, moving beyond incremental gains to enable step-change improvements in cost, speed, and reliability.

For an enterprise of Mylan's size, the volume of structured and unstructured data is enormous—from chemical assay results and production batch records to global logistics feeds and adverse event reports. Historically, leveraging this data has been hampered by siloed systems and manual processes. AI and machine learning offer the tools to synthesize this information, uncover hidden patterns, and automate complex decisions. This is not about replacing human expertise but augmenting it, allowing scientists, supply chain planners, and quality professionals to focus on higher-value tasks while AI handles prediction and routine analysis.

Concrete AI Opportunities with ROI Framing

1. Accelerating Complex Generic & Biosimilar R&D: Developing generic versions of intricate drugs like inhalers or biologics is a costly, multi-year endeavor. AI can dramatically compress timelines. Machine learning models can analyze public and proprietary data on drug patents, molecular interactions, and formulation science to propose viable development pathways. For biosimilars, AI-powered protein modeling can predict structural similarity to the originator molecule. The ROI is direct: reducing time-to-market by even a few months on a blockbuster drug can translate to tens of millions in revenue and solidify market position.

2. Optimizing Global Manufacturing & Supply Chains: Mylan's network of raw material suppliers, API plants, and finished-dose facilities is a complex, interdependent system. AI-driven digital twins can model this entire network, simulating the impact of disruptions like port delays or API shortages. Predictive analytics can forecast demand with greater accuracy, optimizing production schedules and inventory levels across continents. The financial impact is twofold: significant reduction in working capital tied up in inventory and minimization of costly stock-outs that can lead to lost sales and reputational damage in critical markets.

3. Automating Regulatory & Safety Operations: Pharmacovigilance and regulatory submission are massive, manual cost centers. Natural Language Processing (NLP) AI can continuously scan global safety databases, medical literature, and social media in multiple languages to identify potential adverse event signals far faster than manual review. For regulatory filings, AI can help assemble and cross-check massive submission dossiers. This reduces the risk of costly delays from regulatory queries and improves patient safety monitoring. The ROI comes from reduced operational headcount in these areas and decreased risk of post-market regulatory actions.

Deployment Risks Specific to This Size Band

Implementing AI at a 10,000+ employee multinational pharmaceutical company carries unique challenges. First is legacy system integration. Core operations often run on decades-old ERP and Manufacturing Execution Systems (MES). Extracting clean, real-time data from these systems for AI models is a major technical hurdle. Second is data governance and quality. Data is often siloed by business unit, country, or plant, with inconsistent standards. A successful AI program requires a centralized strategy for data stewardship. Third, and most critical, is the regulatory environment. The FDA and other global health authorities require validated, explainable processes. "Black box" AI models are unacceptable. Any AI used in GMP manufacturing or safety reporting must be rigorously validated, documented, and monitored, adding time and cost to deployment. Navigating these risks requires a phased approach, starting with lower-risk pilot areas like predictive maintenance or internal knowledge management, before moving to GxP-critical applications.